CBA shares hit another all-time high. Can they surpass $200 in 2025?

CBA shares have a tailwind pushing up their price that has nothing directly to do with the bank's business performance.

| More on:
A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Commonwealth Bank of Australia (ASX: CBA) shares reset their record high again on Tuesday, rising 2.18% to $188.36.

Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is also up strongly, by 1.09%, following news of the Iran-Israel ceasefire this morning.

Australia's largest bank has been on a tear since the ASX 200 bank stock run began in November 2023.

CBA shares are up by 81% since then.

Could Australia's largest listed company be heading toward the $200 mark?

Let's find out.

CBA shares reset their record

CBA is now the most expensive bank stock in the world, trading at a price-to-earnings (P/E) ratio of 29.34x.

This is significantly higher than its peers, as Tony Locantro of Alto Capital points out.

Courtesy of The Bull, Locantro says:

Relative to its peers, the CBA is expensive.

Westpac Banking Corp (ASX: WBC) was recently trading on a price/earnings ratio of about 16 times and ANZ Group Holdings Ltd (ASX: ANZ) was on 13 times.

In our view, this bank is priced to perfection and is exposed to a correction if economic growth slows.

Investors may want to lock in some profits at these levels.

Locantro is not alone with his sell rating on CBA.

Many other analysts also say it's time to take your profits and run.

There are 15 analysts on the CommSec platform rating CBA shares.

Their consensus rating is a moderate sell. Ten analysts have a strong sell rating, four have a moderate sell rating, and one says hold.

John Athanasiou, CEO of Red Leaf Securities, also thinks investors should hold onto their CBA shares for now.

Some analysts are more excited about some promising ASX small-cap financial shares.

Macquarie is firmly in the sell camp on CBA shares.

In a note released on 17 June, Macquarie reaffirmed its underweight rating and 12-month price target of $105 on CBA shares.

That $105 price target is not a typo.

Macquarie thinks CBA stock is set for an almighty crash to the tune of more than 40% over the next year.

However, CBA has a big tailwind that has nothing directly to do with the bank's business performance.

Could CBA stock go to $200 apiece?

CBA shares are benefiting more than any other stock in the ASX 200 from passive investing.

This is one factor that could keep the CBA share price on an upward path.

CBA shares are directly benefiting from the billions of dollars in investment funds that retail investors (that's an industry term for us ordinary folk) are ploughing into exchange-traded funds (ETFs) tracking major indices such as the ASX 200 and ASX 300.

CBA benefits from this passive investing more than any other ASX stock because it's the largest share by market capitalisation.

The most popular ASX ETF today is the Vanguard Australian Shares Index ETF (ASX: VAS), which tracks the ASX 300 before fees.

Another popular option is the Betashares Australia 200 ETF (ASX: A200), which tracks the benchmark index before fees.

In its May update on ASX ETFs, Betashares reported an eighth consecutive month of more than $3 billion of inflows into ETFs.

Betashares said very strong inflows in May, combined with a positive market performance, pushed the ASX ETF industry to a new record high of $273.7 billion in funds under management.

There are now 425 ASX ETFs trading on the ASX and CBOE exchanges.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Share Gainers

3 ASX 200 stocks storming higher in this week's sinking market

Investors have sent these three ASX 200 stocks soaring this week. But why?

Read more »

Two smiling work colleagues discuss an investment at their office.
Share Gainers

Why 4DMedical, Develop Global, EOS, and Maas shares are racing higher today

These shares are ending the week on a high. But why?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 657% in a year, 4DMedcial shares rocketing another 20% today on big US news

ASX investors can’t get enough of 4DMedical shares today. Let’s see why.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 broke its losing streak to inch higher today.

Read more »

Wife and husband with a laptop on a sofa over the moon at good news.
Consumer Staples & Discretionary Shares

Bapcor shares soar 12% on the appointment of a new CEO

The market’s strong reaction reflects a clear message: investors are ready for a reset.

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Share Gainers

Why Bapcor, IDP Education, Netwealth, and Ora Banda shares are pushing higher today

These shares are catching the eye with solid gains on Thursday. But why are they rising?

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX stock is going parabolic, and I think it's still a buy

4DMedical shares are up nearly 500% in 2025, but improving revenue visibility suggests the growth story may not be over.

Read more »